Shares of Lincoln Pharmaceuticals Limited experienced positive momentum during Thursday intraday trading session, rising 2.15 percent to trade at Rs 624.4 per share on the BSE at 3:15 pm. The Indian drugmaker maintained a market capitalisation of Rs 1,250.66 crore as trading progressed. During the session, the stock fluctuated between an intraday low of Rs 615.30 per share and an intraday high of Rs 624.40 per share. Broking firm Angel One highlighted in its latest research report that the company is well positioned to sustain double-digit growth, driven by its expanding branded-generic product portfolio and increasing market presence in high-margin chronic-therapy segments.
Angel One Buy Rating and Target Price Rationale
In its comprehensive report, Angel One assigned a Buy recommendation to Lincoln Pharmaceuticals Limited, fixing a target price of Rs 845 per share. The brokerage values the stock at approximately 15 times FY27 estimated earnings per share (EPS) of Rs 56. Analyst estimates were revised upwards following an impressive performance in Q1 FY27, where the company recorded a 31 percent year-on-year increase in profit after tax (PAT). According to the brokerage, the target price is solidly backed by a diversified branded-generic portfolio, a robust debt-free balance sheet, an expanding export presence across regulated international markets, and a structured, credible plan to achieve annual revenues of Rs 1,000 crore.
Financial Health and Growth Targets
Lincoln Pharmaceuticals maintains a virtually debt-free balance sheet alongside cash reserves exceeding Rs 200 crore, providing the enterprise with high financial stability. Management has outlined a clear strategic vision to scale total revenue to Rs 1,000 crore over the next three years. The substantial cash surplus gives the company capacity to pursue suitable inorganic growth opportunities, as well as organic expansions such as the potential setup of a greenfield manufacturing facility in Gujarat. Angel One notes that the company is likely to benefit from key emerging operational levers that support both top-line revenue growth and profit margin expansion in upcoming quarters.
Valuation Discount and Sector Comparison
From a valuation perspective, Lincoln Pharmaceuticals currently trades at approximately 14.5 times trailing earnings. This presents a noticeable discount when compared to the broader pharmaceutical sector median valuation of approximately 30 times trailing earnings. Analysts emphasize that this significant valuation gap leaves substantial headroom for a potential stock re-rating as earnings compound over time. The combination of sustained earnings growth, strong chronic-therapy portfolio traction, and export market expansion creates favorable risk reward conditions for investors seeking long-term exposure in the healthcare sector.
Stock Performance and 52-Week Range
The company has delivered solid long-term returns for shareholders. In the current calendar year 2026 so far, the stock price has appreciated by 30 percent, while over a five year investment horizon, shares have surged by approximately 92 percent. The stock retains a healthy return on equity (ROE) of 15.09 percent. Tracking its 52-week trading bounds, Lincoln Pharmaceuticals registered a fresh 52-week high of Rs 770 per share on May 27, 2026, after touching a 52-week low of Rs 439.95 per share on January 28, 2026.
